Related Experiment Videos
Transfusion-acquired HIV infection among immunocompromised hosts
Haematology and Blood Transfusion
|January 1, 1987
Summary
Human Immunodeficiency Virus (HIV) infection in immunocompromised patients shows rapid progression and early seropositivity. Antibody function may predict clinical outcomes in these vulnerable individuals.
Area of Science:
- Immunology
- Virology
- Infectious Diseases
Background:
- Immunocompromised hosts are susceptible to opportunistic infections, including Human Immunodeficiency Virus (HIV).
- Understanding the early clinical and serological manifestations of HIV in this population is crucial for timely diagnosis and management.
Purpose of the Study:
- To characterize the clinical and serological features of HIV infection in immunocompromised individuals.
- To investigate the correlation between antibody function and clinical course.
Main Methods:
- Survey of HIV-infected immunocompromised patients.
- Assessment of clinical sequelae and incubation times.
- Serological testing including Western Blot (WB), Immunocapture assay (RIP), and Enzyme-Linked Immunosorbent Assay (ELISA).
- Evaluation of in vitro neutralizing activity of patient serum antibodies against HIV.
Main Results:
- HIV infection in this cohort presented with a high attack rate and short incubation period to clinical symptoms.
- Western Blot (WB) and RIP seropositivity were detected earlier than Enzyme-Linked Immunosorbent Assay (ELISA) antibody evidence, by weeks to months.
- Functional properties of serum antibodies, including in vitro HIV neutralization, showed a potential correlation with the clinical progression of the disease.
Conclusions:
- HIV infection in immunocompromised hosts has distinct, rapid characteristics.
- Early serological markers (WB, RIP) can precede standard antibody detection (ELISA).
- Functional antibody activity may serve as a prognostic indicator for HIV disease progression in immunocompromised patients.